In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

British Biotech merges with RiboTargets

Executive Summary

Following talks that began in January, British Biotech (matrix metalloproteinase inhibitors, MMPIs) has agreed to merge with RiboTargets (anti-infectives and oncology drugs). RiboTargets' CEO Simon Sturge becomes CEO of the new biotech company, which will be 50.01% owned by the shareholders of BB, and 49.99% by RiboTargets.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Partial Acquisition
    • Payment Includes Stock

Related Companies